Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles

Author： Lanza Gregory M   Winter Patrick M   Caruthers Shelton D   Hughes Michael S   Cyrus Tillmann   Marsh Jon N   Neubauer Anne M   Partlow Kathy C   Wickline Samuel A  

Publisher： Future Medicine

ISSN： 1743-5889

Source： Nanomedicine, Vol.1, Iss.3, 2006-10, pp. : 321-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 278, Iss. 5, 2015-11 ,pp. : 507-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis

By Marsh JN   Senpan A   Hu G   Scott MJ   Gaffney PJ   Wickline SA   Lanza GM  

Nanomedicine, Vol. 2, Iss. 4, 2007-08 ,pp. : 533-543

Future Medicine

Access to resources Recommend Favorite

Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities?

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 162-168

John Wiley & Sons Inc

Access to resources Recommend Favorite

Microfluidic-Assisted Fabrication of Nanoparticles for Nanomedicine Application

By  

Recent Patents on Nanomedicine, Vol. 1, Iss. 2, 2011-12 ,pp. : 109-122

Bentham Science Publishers

Access to resources Recommend Favorite

Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond

By Vázquez Esther   Villaverde Antonio  

Nanomedicine, Vol. 8, Iss. 12, 2013-12 ,pp. : 1895-1898

Future Medicine

Access to resources Recommend Favorite